AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39577821 — intervention group
Group type: EXPERIMENTAL
Intervention: planning + knowledge condition
Number of subjects: 603
Study 39577821 — intervention group
Group type: COMPARATOR
Intervention: knowledge condition
Number of subjects: 603
Study 39577828 — intervention group
Group type: COMPARATOR
Intervention: Control (no prednisone)
Number of subjects: 75
Study 39577828 — intervention group
Group type: EXPERIMENTAL
Intervention: Pred Low (5 mg/d, every other week × 6 months)
Number of subjects: 75
Study 39577828 — intervention group
Group type: EXPERIMENTAL
Intervention: Pred High (20 mg prednisone taper, every other month × 3 months)
Number of subjects: 75
Study 39577828 — intervention group
Group type: EXPERIMENTAL
Intervention: Pred PRN (20 mg prednisone taper × 3 courses maximum if sperm counts were declining or 0)
Number of subjects: 75
Study 39577828 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 75
Study 39577867 — intervention group
Group type: EXPERIMENTAL
Intervention: Indication-based prescribing tool
Number of subjects: 24
Study 39577867 — intervention group
Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 24
Study 39577920 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-start group (100 mg acetylsalicylic acid starting on the third day after surgery until the 90th day)
Number of subjects: 269
Study 39577920 — intervention group
Group type: COMPARATOR
Intervention: Late-start group (100 mg acetylsalicylic acid starting on the 30th day after surgery until the 90th day)
Number of subjects: 269
Study 39577920 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-start group
Number of subjects: 269
Study 39577920 — intervention group
Group type: COMPARATOR
Intervention: Late-start group
Number of subjects: 269
Study 39577921 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glibenclamide (8·6 mg over 72 h)
Number of subjects: 431
Study 39577921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study 39577975 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine-Xpert Ultra
Number of subjects: 1731
Study 39577975 — intervention group
Group type: COMPARATOR
Intervention: AlereLAM
Number of subjects: 1731
Study 39577975 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Sputum-Xpert Ultra with AlereLAM
Number of subjects: 1731
Study 39577975 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Sputum-Xpert Ultra with Urine-Xpert Ultra
Number of subjects: 1731
Study 39577975 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all three tests (Sputum-Xpert Ultra, AlereLAM, Urine-Xpert Ultra)
Number of subjects: 1731
Study 39578022 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Number of subjects: 500
Study 39578022 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application for patient-reported outcomes
Number of subjects: 500
Study 39578039 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Activated Reliever-Triggered ICS (PARTICS)
Number of subjects: 713
Study 39578039 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 713
Study 39578038 — intervention group
Group type: EXPERIMENTAL
Intervention: DOR/DTG/3TC (co-formulated doravirine, dolutegravir, and lamivudine) once daily
Number of subjects: 210
Study 39578038 — intervention group
Group type: COMPARATOR
Intervention: Boosted ART regimen
Number of subjects: 210
Study 39578038 — intervention group
Group type: EXPERIMENTAL
Intervention: DOR/DTG/3TC
Number of subjects: 210
Study 39578040 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic patients with active COVID-19
Number of subjects: 311
Study 39578040 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic patients with active COVID-19
Number of subjects: 311
Study 39578040 — intervention group
Group type: COMPARATOR
Intervention: Patients who had recovered from COVID-19 prior to surgery
Number of subjects: 311
Study 39578265 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula (HFNC) at 50 to 60 L.min
Number of subjects: 29
Study 39578265 — intervention group
Group type: COMPARATOR
Intervention: Low-level continuous positive airway pressure (CPAP) at 4 cmH2O
Number of subjects: 29
Study 39578309 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES-RT + FES
Number of subjects: 32
Study 39578309 — intervention group
Group type: COMPARATOR
Intervention: PMT + FES
Number of subjects: 32
Study 39578309 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 32
Study 39578347 — intervention group
Group type: EXPERIMENTAL
Intervention: GN-037 cream
Number of subjects: 190
Study 39578347 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol 17-propionate (CP) cream
Number of subjects: 190
Study 39578347 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (V) cream
Number of subjects: 190
Study 39578347 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 190
Study 39578348 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Number of subjects: 1107
Study 39578348 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab 320 mg every 4 weeks (Q4W)/every 8 weeks (Q8W) initial/maintenance dosing
Number of subjects: 1107
Study 39578376 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe periodontitis
Number of subjects: 1002
Study 39578376 — intervention group
Group type: COMPARATOR
Intervention: Tooth brushing more than once a day
Number of subjects: 1002
Study 39578376 — intervention group
Group type: COMPARATOR
Intervention: Interdental hygiene
Number of subjects: 1002
Study 39578602 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative vaginal microbiome analysis
Number of subjects: 22
Study 39578602 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal microbiome characterized by low abundance of Lactobacillus and high prevalence of Prevotella and Gardnerella species
Number of subjects: 22
Study 39578778 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-cholesterol levels in women
Number of subjects: 231
Study 39578778 — intervention group
Group type: COMPARATOR
Intervention: Obesity and serum leptin levels
Number of subjects: 231
Study 39578819 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-20 levels in patients with MetS and periodontitis
Number of subjects: 80
Study 39578819 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of IL-20 with periodontal parameters
Number of subjects: 80
Study 39578819 — intervention group
Group type: EXPERIMENTAL
Intervention: RANKL/OPG levels correlation with IL-20
Number of subjects: 80
Study 39578819 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidative stress index (OSI) levels in presence of periodontitis and MetS
Number of subjects: 80
Study 39578921 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% topical sirolimus applied to the face for 24 weeks
Number of subjects: 146
Study 39578921 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied to the face for 24 weeks
Number of subjects: 146
Study 39578921 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% topical sirolimus
Number of subjects: 146
Study 39578921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 39578926 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic deprescribing intervention
Number of subjects: 344
Study 39578926 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 344
Study 39578942 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD-CAM surgical guides
Number of subjects: 27
Study 39578942 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical guides (control group)
Number of subjects: 27
Study 39579142 — intervention group
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Number of subjects: 326
Study 39579142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326
Study 39579225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular fibrillation (VF)
Number of subjects: 30
Study 39579225 — intervention group
Group type: COMPARATOR
Intervention: No ventricular fibrillation (Control)
Number of subjects: 30
Study 39579274 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week progressive whole-body resistance exercise training (RET) program
Number of subjects: 13
Study 39579274 — intervention group
Group type: COMPARATOR
Intervention: Control group (postmenopausal breast cancer survivors)
Number of subjects: 13
Study 39579383 — intervention group
Group type: EXPERIMENTAL
Intervention: KIM technology for real-time image-guided radiotherapy
Number of subjects: 48
Study 39579408 — intervention group
Group type: COMPARATOR
Intervention: Hyperpronation (HP) maneuver
Number of subjects: 119
Study 39579408 — intervention group
Group type: EXPERIMENTAL
Intervention: Supination/Flexion (SF) maneuver
Number of subjects: 119
Study 39579605 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (4 group sessions and 6 telephone calls over 6 months) focusing on physical activity, nutritional habits, cognition, and psychosocial well-being
Number of subjects: 199
Study 39579605 — intervention group
Group type: COMPARATOR
Intervention: Usual healthcare assistance (Control group)
Number of subjects: 199
Study 39579782 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon guide catheter
Number of subjects: 329
Study 39579782 — intervention group
Group type: COMPARATOR
Intervention: Conventional guide catheter
Number of subjects: 329
Study 39579782 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 329
Study 39580145 — intervention group
Group type: EXPERIMENTAL
Intervention: Faricimab 6.0 mg every 8 weeks (Q8W)
Number of subjects: 1809
Study 39580145 — intervention group
Group type: EXPERIMENTAL
Intervention: Faricimab 6.0 mg according to a personalized treat-and-extend (T&E)-based regimen
Number of subjects: 1809
Study 39580145 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept 2.0 mg every 8 weeks (Q8W)
Number of subjects: 1809
Study 39580357 — intervention group
Group type: EXPERIMENTAL
Intervention: EASE-TR before performance
Number of subjects: 100
Study 39580357 — intervention group
Group type: EXPERIMENTAL
Intervention: EASE-TR after performance
Number of subjects: 100
Study 39580357 — intervention group
Group type: EXPERIMENTAL
Intervention: EASE-TR
Number of subjects: 100
Study 39580383 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet supplemented with soybeans (n=42)
Number of subjects: 84
Study 39580383 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=42)
Number of subjects: 84
Study 39580437 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical antibiotic therapy
Number of subjects: 523
Study 39580437 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to guidelines for empirical antibiotic therapy
Number of subjects: 523
Study 39580437 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to guidelines for therapy duration
Number of subjects: 523
Study 39580437 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) level exceeding 100 mg/L
Number of subjects: 523
Study 39580437 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital stay longer than two days
Number of subjects: 523
Study 39580437 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned post-discharge treatment
Number of subjects: 523
Study 39580437 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal trends in adherence to treatment duration guidelines
Number of subjects: 523
Study 39580468 — intervention group
Group type: EXPERIMENTAL
Intervention: AADvac1
Number of subjects: 137
Study 39580601 — intervention group
Group type: EXPERIMENTAL
Intervention: High Synek scale (3 or 4)
Number of subjects: 125
Study 39580601 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG features (discontinuity)
Number of subjects: 125
Study 39580601 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG features (absence of posterior dominant rhythm)
Number of subjects: 125
Study 39580622 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal loci associated with HDP (rs114954125 on chromosome 2 near LRP1B)
Number of subjects: 0
Study 39580793 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea and chronic transfusion therapy (HAT)
Number of subjects: 14
Study 39580964 — intervention group
Group type: EXPERIMENTAL
Intervention: LPG-STJI (single-tract jejunal interposition)
Number of subjects: 124
Study 39580964 — intervention group
Group type: EXPERIMENTAL
Intervention: LPG-DTR (double-tract reconstruction)
Number of subjects: 124
Study 39580964 — intervention group
Group type: COMPARATOR
Intervention: LPG-TLR (tube-like stomach reconstruction)
Number of subjects: 124
Study 39580964 — intervention group
Group type: EXPERIMENTAL
Intervention: LPG-STJI
Number of subjects: 124
Study 39580964 — intervention group
Group type: EXPERIMENTAL
Intervention: LPG-DTR
Number of subjects: 124
Study 39580964 — intervention group
Group type: COMPARATOR
Intervention: LPG-TLR
Number of subjects: 124
Study 39581179 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum (BC)
Number of subjects: 219
Study 39581179 — intervention group
Group type: COMPARATOR
Intervention: Conventional fortifier (CF)
Number of subjects: 219
Study 39581180 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA-enriched medium/long-chain triglyceride (MCT/LCT) lipid emulsion (Lipidem)
Number of subjects: 74
Study 39581180 — intervention group
Group type: COMPARATOR
Intervention: Standard medium/long-chain triglyceride (MCT/LCT) lipid emulsion (reference group)
Number of subjects: 74
Study 39581197 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab 200 mg plus platinum-based doublet chemotherapy followed by adjuvant tislelizumab 400 mg every 6 weeks.
Number of subjects: 453
Study 39581197 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus platinum-based doublet chemotherapy followed by placebo every 6 weeks.
Number of subjects: 453
Study 39581202 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab 900 mg IV at weeks 0, 4, and 8, then 300 mg SC every 4 weeks from weeks 12 to 52
Number of subjects: 1150
Study 39581202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1150
Study 39581202 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Number of subjects: 1150
Study 39581202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 1150
Study 39581330 — intervention group
Group type: EXPERIMENTAL
Intervention: Lampalizumab intervention (exact details not provided)
Number of subjects: 0
Study 39581330 — intervention group
Group type: EXPERIMENTAL
Intervention: GA growth rate quartiles
Number of subjects: 0
Study 39581330 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-to-event analysis for BCVA loss
Number of subjects: 0
Study 39581330 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox regression model adjusted for baseline factors
Number of subjects: 0
Study 39581380 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg orally once daily in continuous 21-day cycles
Number of subjects: 367
Study 39581426 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular leadless pacemaker (VR-LP)
Number of subjects: 17
Study 39581426 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial leadless pacemaker (AR-LP)
Number of subjects: 17
Study 39581486 — intervention group
Group type: EXPERIMENTAL
Intervention: Cu 175 mm intrauterine device
Number of subjects: 1620
Study 39581541 — intervention group
Group type: EXPERIMENTAL
Intervention: Rezafungin
Number of subjects: 294
Study 39581541 — intervention group
Group type: COMPARATOR
Intervention: Caspofungin
Number of subjects: 294
Study 39581631 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenerimod 4 mg
Number of subjects: 0
Study 39581631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39581631 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenerimod 2 mg
Number of subjects: 0
Study 39581701 — intervention group
Group type: COMPARATOR
Intervention: Increased VMHC values in the insula and parahippocampal gyrus in patients with SLE compared to HCs
Number of subjects: 54
Study 39581701 — intervention group
Group type: COMPARATOR
Intervention: Reduced grey matter volume in insula and parahippocampal gyrus in patients with SLE compared to HCs
Number of subjects: 54
Study 39581701 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of VMHC values and grey matter volume with cognitive scores and blood biochemical markers in patients with SLE
Number of subjects: 54
Study 39581714 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-value practices (LVPs) prescribed to female patients
Number of subjects: 978936
Study 39581714 — intervention group
Group type: COMPARATOR
Intervention: Low-value practices (LVPs) prescribed to male patients
Number of subjects: 978936
Study 39581714 — intervention group
Group type: EXPERIMENTAL
Intervention: Common low-value practices identified
Number of subjects: 978936
Study 39581721 — intervention group
Group type: EXPERIMENTAL
Intervention: Diurnal intermittent enteral nutrition
Number of subjects: 30
Study 39581721 — intervention group
Group type: COMPARATOR
Intervention: Continuous enteral feeding
Number of subjects: 30
Study 39581722 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria molecular surveillance
Number of subjects: 0
Study 39581722 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategic plan of the Mozambican National Malaria Control Programme (2023-2030)
Number of subjects: 0
Study 39581724 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterosalpingography (HSG) with oil-based contrast medium
Number of subjects: 1102
Study 39581724 — intervention group
Group type: COMPARATOR
Intervention: Hysterosalpingo-foam sonography (HyFoSy)
Number of subjects: 1102
Study 39581725 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspected preterm labour (SPL)
Number of subjects: 0
Study 39581725 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (not exposed to SPL)
Number of subjects: 0
Study 39581725 — intervention group
Group type: EXPERIMENTAL
Intervention: SPL group
Number of subjects: 0
Study 39581725 — intervention group
Group type: EXPERIMENTAL
Intervention: Children from SPL group
Number of subjects: 0
Study 39581725 — intervention group
Group type: COMPARATOR
Intervention: Children from matched controls
Number of subjects: 0
Study 39581729 — intervention group
Group type: EXPERIMENTAL
Intervention: 1L therapy (first systemic treatment for A/R EC with or without radiotherapy)
Number of subjects: 2376
Study 39581729 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin-paclitaxel at 1L
Number of subjects: 2376
Study 39581737 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart About Meds (SAM) mobile application
Number of subjects: 3250
Study 39581737 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3250
Study 39581739 — intervention group
Group type: COMPARATOR
Intervention: HIV self-testing (HIVST) alone (standard of care)
Number of subjects: 330
Study 39581739 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health (mHealth) and graphic medicine (comic) programme for mental health alongside HIVST
Number of subjects: 330
Study 39581739 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of HIVST, a livelihoods programme, and mHealth mental health programme
Number of subjects: 330
Study 39581887 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 implants (4-I)
Number of subjects: 47
Study 39581887 — intervention group
Group type: COMPARATOR
Intervention: 6 implants (6-I)
Number of subjects: 47
Study 39581892 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus endocrine therapy (ET)
Number of subjects: 1250
Study 39581908 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESAs)
Number of subjects: 85259
Study 39581957 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous omadacycline 100 mg over 0.5 h
Number of subjects: 9
Study 39581957 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral omadacycline 300 mg
Number of subjects: 9
Study 39582029 — intervention group
Group type: EXPERIMENTAL
Intervention: 750,000 IU of vitamin D3 via enteral or oral route
Number of subjects: 138
Study 39582029 — intervention group
Group type: COMPARATOR
Intervention: 500,000 IU of vitamin D3
Number of subjects: 138
Study 39582048 — intervention group
Group type: EXPERIMENTAL
Intervention: Curability belief
Number of subjects: 382
Study 39582048 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression (PHQ-9 score ≥ 10)
Number of subjects: 382
Study 39582048 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of curability belief and depression
Number of subjects: 382
Study 39582048 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspended/stopped anti-cancer treatment
Number of subjects: 382
Study 39582048 — intervention group
Group type: EXPERIMENTAL
Intervention: End-of-life care settings
Number of subjects: 382
Study 39582128 — intervention group
Group type: EXPERIMENTAL
Intervention: LY06006
Number of subjects: 300
Study 39582128 — intervention group
Group type: EXPERIMENTAL
Intervention: EU-DEN
Number of subjects: 300
Study 39582128 — intervention group
Group type: EXPERIMENTAL
Intervention: US-DEN
Number of subjects: 300
Study 39582355 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional Care Model (TCM) intervention
Number of subjects: 78
Study 39582503 — intervention group
Group type: EXPERIMENTAL
Intervention: 3HP (isoniazid and rifapentine)
Number of subjects: 1655
Study 39582544 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) protocol
Number of subjects: 611
Study 39582544 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 611
Study 39582551 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Auricular Acupressure Group (AAG)
Number of subjects: 35
Study 39582551 — intervention group
Group type: COMPARATOR
Intervention: Sham Auricular Acupressure Group (SAG)
Number of subjects: 35
Study 39582666 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrosomial Vitamin B12 supplementation
Number of subjects: 0
Study 39582666 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39582705 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced 6-month cardiac rehabilitation program combining exercise training with nutritional intervention (reduction of ultraprocessed food intake, Mediterranean diet, time-restricted eating)
Number of subjects: 36
Study 39582705 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced 6-month cardiac rehabilitation program
Number of subjects: 36
Study 39582898 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolbetuximab plus CAPOX
Number of subjects: 0
Study 39582898 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus CAPOX
Number of subjects: 0